Focused On-demand Library for Cyclic nucleotide-gated cation channel beta-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14028

UPID:

CNGB1_HUMAN

Alternative names:

Cyclic nucleotide-gated cation channel 4; Cyclic nucleotide-gated cation channel gamma; Cyclic nucleotide-gated cation channel modulatory subunit; Cyclic nucleotide-gated channel beta-1; Glutamic acid-rich protein

Alternative UPACC:

Q14028; H3BN09; O43636; Q13059; Q14029; Q9UMG2

Background:

Cyclic nucleotide-gated cation channel beta-1, also known as CNG channel beta-1, plays a pivotal role in visual and olfactory signal transduction. It forms a crucial part of cyclic nucleotide-gated (CNG) channels, facilitating the regulation of ion flow into rod photoreceptor outer segments in response to changes in intracellular cGMP levels. This protein's functionality is enhanced by its isoform GARP2, which modulates rod photoreceptor phosphodiesterase activity, crucial for minimizing 'dark noise' and enabling photon detection.

Therapeutic significance:

Given its critical role in visual processes, Cyclic nucleotide-gated cation channel beta-1 is directly implicated in Retinitis pigmentosa 45, a retinal dystrophy characterized by night vision blindness and progressive loss of visual field. Understanding the protein's function and its genetic variants could pave the way for innovative treatments targeting the underlying mechanisms of this and potentially other related visual disorders.